Beijing, China, November 15, 2025 – Bayer Co. Lab was officially launched in Yizhuang BioPark, with Puhe BioPharma settling in as one of the first batch of companies.

Puhe BioPharma is dedicated to the research and development of small-molecule precision therapeutics and licensed a PRMT5 small-molecule inhibitor (BAY3713372) that selectively targets MTAP-deleted tumors to Bayer in March 2025. Under the partnership, Puhe and Bayer will explore more diverse collaborations, especially in the fields of cancers, autoimmune diseases, and various chronic diseases. Furthermore, Puhe will utilize Bayer’s global R&D capabilities and commercial networks to launch more innovative drugs in overseas markets.

Welcoming the first batch of companies settled in Bayer Co. Lab: Alberto Nobili, Global Representative of Bayer Co. Lab (1st from right) and Yongqi Guo, CEO of Puhe BioPharma (2nd from right).

Bayer is the only biopharmaceutical company whose Beijing branch’s annual output value exceeds 10 billion RMB for 13 consecutive years. It is also among the few foreign-funded companies in Beijing to operate both a “Global R&D Center” and a world-class “Product Supply Center”. Bayer’s Beijing Prescription Drug Factory has become the largest prescription drug packaging base in Bayer’s global network. Yizhuang Bayer Co. Lab is the first innovation center established by Bayer in China. Its official launch marks an important step for Bayer to deepen its strategic layout in China’s biotech sector, further demonstrating its confidence in long-term investment and development in China.

About Bayer

As an MNC, Bayer possesses core competitiveness in healthcare and agriculture. Upholding its mission of “Health for All, Hunger for None”, Bayer is committed to helping people address the major challenges posed by global population growth and aging through its products and services, contributing to the prosperity of humanity and the planet. Bayer is dedicated to driving sustainable development, enhancing profitability and creating value through technological innovation and business growth. Globally, Bayer stands for trust, reliability and quality. In the 2024 fiscal year, Bayer employed approximately 93,000 people and achieved sales of €46.6 billion. Its R&D investment excluding special items reached €6.2 billion. For more information, please visit www.bayer.com.

About Puhe BioPharma

Suzhou Puhe BioPharma Co., Ltd. is a biotechnology company dedicated to the research and development of innovative small-molecule precision therapeutics. Adhering to the strategy of addressing differential clinical needs, Puhe focuses on cancers with high incidence and mortality rates as well as other chronic diseases. By leveraging scientific and industrial expertise, Puhe combines various advanced technologies such as the next-generation kinase inhibitors, synthetic lethality, PROTACs, and molecular glues to address complex medical challenges. For more information, please visit www.puhebiopharma.com.